Skip to main content
SpringerLink
Log in

Anti-Inflammatory Effects of Intravenous Immunoglobulin

  • Conference paper
Symposium in Immunology VIII

  • 59 Accesses

Abstract

Intravenous immunoglobulin (IVIg) is a therapeutic preparation of normal human polyspecific immunoglobulin (Ig) G obtained from pooled plasma of a large number of healthy donors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abe J, Kotzin BL, Meissner C, Melish ME, Takahshi M, Fulton D, Romagne F, Me- lissen B, Leung DYM (1993) Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 177: 791 – 796

    Article  PubMed  CAS  Google Scholar 

  • Abe Y, Horiuchi A, Miyake M, Kimura S (1994) Anti-cytokine nature of human immunoglobulin: one possible mechanism of the clinical effect of intravenous therapy. Immunol Rev 139: 5 – 19

    Article  PubMed  CAS  Google Scholar 

  • Achiron A, Barak Y, Sarova-Pinhas I, Achiron R, Gabbay U, Rotstein Z, Noy S (1996) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis. In: Kazatchkine MD, Morel A (eds) Intravenous immunoglobulin research and therapy. Parthenon Publishing Group Ltd., London, pp 289 – 294

    Google Scholar 

  • Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, Cohen IR, Lider O (1994) Intravenous immunoglobulin treatment of experimental T cell- mediated autoimmune disease. Upregulation of T cell proliferation and downreg- ulation of tumor necrosis factor alpha secretion. J Clin Invest 93: 600 – 605

    Article  PubMed  CAS  Google Scholar 

  • Amran A, Renz H, Lack G, Bradley K, Gelfand EW (1994) Suppression of cytokine- dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 73:180-186 Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP (1994) Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139: 21 – 42

    Article  Google Scholar 

  • Antonelli A, Palla R, Casarosa L, Fallahi P, Baschieri L (1996) IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves’ disease: their in vitro solubilization by intravenous immunoglobulin. Clin Exp Rheumatol 14 (Suppl 15): S31 – S35

    PubMed  Google Scholar 

  • Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr 113: 1008 – 1014

    Article  PubMed  CAS  Google Scholar 

  • Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T (1994) Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84: 2136 – 2143

    PubMed  CAS  Google Scholar 

  • Aukrust P, Hestdal K, Lien E, Bjerkeli V, Nordoy I, Espevik T, Muller F, Frolland SS (1997) Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis 176: 913 – 923

    Article  PubMed  CAS  Google Scholar 

  • Basta M (1996) Modulation of complement-mediated tissue damage by intravenous immunoglobulin. In: Kazatchkine MD, Morell A (eds) Intravenous immunoglobulin and therapy. Parthenon, New York, pp 83 – 88

    Google Scholar 

  • Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Invest 94: 1729 – 1735

    Article  PubMed  CAS  Google Scholar 

  • Basta M, Kirshbom P, Frank MM, Fries LF (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement dependent immune damage in a guinea pig model. J Clin Invest 84: 1974 – 1981

    Article  PubMed  CAS  Google Scholar 

  • Basta M, Langlois PF, Marques M, Frank MM, Fries LF (1989) High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74: 326 – 333

    PubMed  CAS  Google Scholar 

  • Baudet V, Hurez V, Lapeyre C, Kaveri SV, Kazatchkine MD (1996) Intravenous immunoglobulin (IVIg) enhances the selective expansion of Vb3+ and Vbl7+ ab T cells induced by superantigen. Scand J Immunol 43: 277 – 282

    Article  PubMed  CAS  Google Scholar 

  • Beckers RC, Brand A, Vermeer BJ, Boom BW (1995) Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 133: 289 – 293

    Article  PubMed  CAS  Google Scholar 

  • Bendtzen K, Svenson M, Jonsson V, Hippe E (1990) Autoantibodies to cytokines friends or foes Immunol Today 11: 167 – 169

    Article  PubMed  CAS  Google Scholar 

  • Blanchette VS, Imbach P, Andrew M (1994) A prospective randomized trial of intravenous immunoglobulin G, oral prednisolone and intravenous anti-D in childhood acute idiopathic thrombocytopenic purpura. Lancet 344: 703 – 707

    Article  PubMed  CAS  Google Scholar 

  • Blasczyk R, Westhoff U, Grossewilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341: 789 – 790

    Article  PubMed  CAS  Google Scholar 

  • Brady HR (1994) Leukocyte adhesion molecules and kidney diseases. Kidney Int 45: 1285 – 1300

    Article  PubMed  CAS  Google Scholar 

  • Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84: 2068 – 2101

    PubMed  CAS  Google Scholar 

  • Dalakas M, Ilia I, Dambrosia J, Soueidan S, Stein D, Otero C, Dinsmore S, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993 – 2000

    Article  PubMed  CAS  Google Scholar 

  • Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326: 107 – 116

    Article  PubMed  CAS  Google Scholar 

  • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoll B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing remitting sclerosis. Lancet 349: 589 – 593

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Imai K, Matsubara T, Yone K, Yachi A, Okumura K, Yabuta K (1992) Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. Arthritis Rheum 35: 672 – 677

    Article  PubMed  CAS  Google Scholar 

  • Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, Kawarano M, Baba K, Mori C (1984) High- dose intravenous gammaglobulin for Kawasaki disease. Lancet ii: 1055 – 1058

    Google Scholar 

  • Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol 41: 89 – 96

    Article  Google Scholar 

  • Gajdos P, Outin H, Elkharrat D, Brunei D, Rohan-Chabot PD, Raphael JC, Goulon M, Goulon-Goeau C, Morel E (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet i: 406 – 407

    Google Scholar 

  • Gedalia A, Correa H, Kaiser M, Sorensen R (1995) Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am J Med Sci 309: 226 – 228

    Article  PubMed  CAS  Google Scholar 

  • Gelfand EW, Esterl B, Mazer BD (1994) Benefit of 12% solution of intravenous immunoglobulin in the treatment of steroid-dependent asthma. In: Kazatchkine MD, Louwagie A (eds) Immunoglobulins extending the horizons. Parthenon Publ, London, pp 49 – 62

    Google Scholar 

  • George F, Goichot L, Francois A, Castiel P, Kulmann N, Cassoux N, LeHoang P, Kazatchkine MD (1996) Corticosteroid-sparing effect of intravenous immunoglobulin in birdshot retinochoroidopathy. In: Kazatchkine MD, Morell A (eds) Intravenous immunoglobulin and therapy. Parthenon, New York, pp 333 – 334

    Google Scholar 

  • Hahn AF, Bolton CF, Zochodone D, Feasby TE (1995) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy (CIDP): a dou- ble-blind, placebo-controlled study. Brain 119: 1067 – 1078

    Article  Google Scholar 

  • Hughes R, Plasma exchange/Sandoglobulin Guillain-Barre syndrome trial group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barre syndrome. Lancet 349: 225 – 230

    Article  Google Scholar 

  • Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet i: 1228 – 1230

    Google Scholar 

  • Jayne DRW, Davies M, Fox C, Lockwood CM (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet ii: 1137 – 1139

    Google Scholar 

  • Karmochkine M, Cassoux N, Goichot-Bonnat L, Lehoang P, Kazatchkine MD (1998) Steroid-sparing effect of intravenous immunoglobulin in inflammatory uveitis. (Submitted )

    Google Scholar 

  • Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV (1994) V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139: 79 – 107

    Article  PubMed  CAS  Google Scholar 

  • Lalezari P, Korshidi M, Petrosova M (1986) Autoimmune neutropenia of infancy. J Pediatr 109: 764 – 769

    Article  PubMed  CAS  Google Scholar 

  • Latremouille C, Genevaz D, Hu MC, Schussler O, Goussev N, Bruneval P, Haeffner- Cavaillon N, Carpentier A, Glotz D (1997) Normal human polyclonal immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab’)2-niediated anti-complement activity. Clin Exp Immunol 110: 122 – 126

    Article  PubMed  CAS  Google Scholar 

  • LeHoang P, Jobin D, Kazatchkine MD (1998) Treatment of birdshot retinochoroidopathy with intravenous immunoglobulins. (Submitted) Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ (1996) High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88: 184 – 193

    Google Scholar 

  • McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, Hoffman R (1987) Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gammaglobulin. N Engl J Med 317: 1004 – 1008

    Article  PubMed  CAS  Google Scholar 

  • Mclntyre EA, Linch DC, Macey MG, Newland AC (1985) Successful response to intravenous immunoglobulin in autoimmune hemolytic anemia. Br J Haematol 60: 387 – 388

    Article  Google Scholar 

  • Menezes MC, Benard G, Sato MN, Hong MA, Duarte AJ (1997) In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol 114: 323 – 328

    Article  PubMed  CAS  Google Scholar 

  • Miletic VD, Hester CG, Frank MM (1996) Regulation of complement activity by immunoglobulin. J Immunol 156:749–757

    Google Scholar 

  • Mollnes TE, Hogasen K, Hoas BF, Michaelsen TE, Garred P, Harboe M (1995) Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its CI binding properties. Scand J Immunol 41: 449 – 456

    Article  PubMed  CAS  Google Scholar 

  • Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD (1996) Mechanisms of action of intravenous immune globulins in immune-mediated diseases. Clin Exp Immunol 104: 3 – 9

    PubMed  CAS  Google Scholar 

  • Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders RP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 315: 341 – 347

    Article  PubMed  CAS  Google Scholar 

  • Nomura S, Yasunaga K, Fujimura K, Kuramoto A, Okuma M, Nomura T (1996) High- dose intravenous gamma globulin reduces macrophage colony-stimulating factor levels in idiopathic thrombocytopenic purpura. Int J Hematol 63: 227 – 234

    Article  PubMed  CAS  Google Scholar 

  • Oda H, Honda A, Sugita K (1985) High dose intact IgG infusion in refractory autoimmune hemolytic anemia (Evans syndrome). J Pediatr 107: 744 – 746

    Article  PubMed  CAS  Google Scholar 

  • Pashov A, Bellon B, Kaveri SV, Kazatchkine MD (1997) A shift in encephalogenic T cell pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Multiple Sclerosis 3: 153 – 156

    Article  PubMed  CAS  Google Scholar 

  • Poutsiaka DD, Clark BD, Vannier E, Dinarello CA (1991) Production of IL-receptor antagonist and IL-lß by peripheral blood mononuclear cells is differentially regulated. Blood 78: 1275 – 1279

    PubMed  CAS  Google Scholar 

  • Rossi F, Bellon B, Vial MC, Druet P, Kazatchkine MD (1991) Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride- induced autoimmune disease of Brown-Norway rats. Clin Exp Immunol 84: 129 – 133

    Article  PubMed  CAS  Google Scholar 

  • Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N (1995) Selective induction of interleukin- 1 receptor antagonist and interleukin-8 in human monocytes by normal polyspe- cific IgG (intravenous immunoglobulin). Eur J Immunol 25: 1267 – 1273

    Article  PubMed  CAS  Google Scholar 

  • Sato M, Kojima H, Koshikawa SJ (1986) Modification of immune complexes deposited in glomeruli in tissue sections treated with sulfonized gamma-globulin. Clin Exp Immunol 64: 623 – 628

    PubMed  CAS  Google Scholar 

  • Schmidt RE, Budde V, Schäfer G, Stroehmann I (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet ii: 475 – 476

    Google Scholar 

  • Shimozato T, Iwata M, Kawada H, Tamura N (1990) Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 58: 1384 – 1388

    PubMed  CAS  Google Scholar 

  • Shimozato T, Iwata M, Kawada H, Tamura N (1991) Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3’: 5’- monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 72: 497 – 501

    PubMed  CAS  Google Scholar 

  • Shulman ST (1992) Recommendations for intravenous immunoglobulin therapy of Kawasaki disease. Pediatr Infect Dis J 11: 985 – 986

    Article  PubMed  CAS  Google Scholar 

  • Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE (1984) Anti-idiotypic suppression of autoantibodies to Factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet ii: 765 – 768

    Google Scholar 

  • Svenson M, Hansen MB, Bendtzen K (1990) Distribution and characterization of autoantibodies to interleukin la in normal human sera. Scand J Immunol 32: 695 – 701

    Article  PubMed  CAS  Google Scholar 

  • Takei S, Arora Y, Walker SM (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superanti- gens. J Clin Invest 91: 602 – 607

    Article  PubMed  CAS  Google Scholar 

  • Taprantzi P, Syrigou E, Zervaki K, Andriani E, Papdoulous N, Sinaniotis C, Saxoni- Papgeorgiou F (1996) Low-dose intravenous immunoglobulin in severe steroid- dependent childhood asthma. In: Kazatchkine MD, Morell A (eds) Intravenous immunoglobulin and therapy. Parthenon, New York, p 332

    Google Scholar 

  • Tekow J, Reinhold D, Pap T, Ansorge S (1998) Intravenous immunoglobulins and transforming growth factor-ß. Lancet 351: 184 - 185

    Article  Google Scholar 

  • Tomino Y, Sakai H, Takaya M, Miura M, Suga T, Endoh M, Nomoto Y (1984) Solubilization of intraglomerular deposits of IgG immune complexes by human sera or gammaglobulin in patients with lupus nephritis. Clin Exp Immunol 58: 42 – 48

    PubMed  CAS  Google Scholar 

  • Tomita S, Myones BL, Shulman ST (1993) In vitro correlates of the L. casei animal model of Kawasaki disease. J Rheumatol 20: 362 – 367

    PubMed  CAS  Google Scholar 

  • Toungouz M, Denys C, Dupont E (1996) Blockade of proliferation and tumor necrosis factor-alpha production occuring during mixed lymphocyte reaction by inter- feron-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 62: 1292 – 1296

    Article  PubMed  CAS  Google Scholar 

  • van der Meché FGA, Smith PIM, Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326: 1123 – 1129

    Article  PubMed  Google Scholar 

  • Xu C, Poirier B, Lavaud S, Lucchiari N, Michel O, Chevalier J, Kaveri S (1998) Modulation of endothelial cell function by normal polyspecific human immunoglobulins: a possible mechanism of action of in vascular diseases. Amer J Pathol (Submitted)

    Google Scholar 

  • Yuki N, Ichihashi Y, Taki T (1995) Subclass of IgG antibody to GM1 epitope-bear- ing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J Neuroimmunol 60: 161 – 164

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Y. Bar-Dayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. V. Kaveri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Bar-Dayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Pashov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. D. Kazatchkine
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Immunologie der Universität Wien, Borschkegasse 8 a, 1090, Wien, Austria

    Martha M. Eibl

  2. Department of Hematology, Johannes Gutenberg Universität, Langenbeckstr. 1, 55101, Mainz, Germany

    Christoph Huber

  3. Abteilung Für Rheumatologie und Klinische Immunologie, Medizinische Universitätsklinik, Hugstetter Str. 55, 79106, Freiburg, Germany

    Hans H. Peter

  4. Pädiatrische Pneumologie und Immunologie, Universitäts-Klinikum Rudolf-Virchow Standort Charlottenburg, Heubnerweg 6, 14059, Berlin, Germany

    Ulrich Wahn

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bar-Dayan, Y., Kaveri, S.V., Bar-Dayan, Y., Pashov, A., Shoenfeld, Y., Kazatchkine, M.D. (1999). Anti-Inflammatory Effects of Intravenous Immunoglobulin. In: Eibl, M.M., Huber, C., Peter, H.H., Wahn, U. (eds) Symposium in Immunology VIII. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59947-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59947-7_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-64722-5

  • Online ISBN: 978-3-642-59947-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation